Mucopolysaccharidosis II - Pipeline Review, H1 2017
Mucopolysaccharidosis II - Pipeline Review, H1 2017
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II - Pipeline Review, H1 2017, provides an overview of the Mucopolysaccharidosis II (Metabolic Disorders) pipeline landscape.
Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial features, including thickening of the lips, tongue and nostrils and delayed development. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mucopolysaccharidosis II - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Mucopolysaccharidosis II (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 5, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Mucopolysaccharidosis II (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II - Pipeline Review, H1 2017, provides an overview of the Mucopolysaccharidosis II (Metabolic Disorders) pipeline landscape.
Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial features, including thickening of the lips, tongue and nostrils and delayed development. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mucopolysaccharidosis II - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Mucopolysaccharidosis II (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 5, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Mucopolysaccharidosis II (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis II (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Mucopolysaccharidosis II (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Mucopolysaccharidosis II (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Mucopolysaccharidosis II (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis II (Metabolic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mucopolysaccharidosis II (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Overview
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Companies Involved in Therapeutics Development
AngioChem Inc
ArmaGen Inc
Bioasis Technologies Inc
Green Cross Corp
Inventiva
JCR Pharmaceuticals Co Ltd
Laboratorios Del Dr Esteve SA
RegenxBio Inc
Sangamo Therapeutics Inc
Shire Plc
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Drug Profiles
AGT-182 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EGT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase beta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JR-032 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JR-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTf-I2S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTfp-I2S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
odiparcil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-913 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Product Development Milestones
Featured News & Press Releases
Oct 26, 2016: National Center for Child Health and Development Initiates Phase 1/2 Trial of Green Cross' idursulfase-beta ICV for the Treatment of Hunter Syndrome with Neurocognitive Decline
Sep 13, 2016: REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV Gene Therapy RGX-121
Jul 05, 2016: REGENXBIO Provides Update On Gene Therapy Development Program RGX-121
Apr 19, 2016: Preclinical Data from REGENXBIO’s RGX-121 Gene Therapy Program to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting
Feb 25, 2016: ESTEVE Provides Update On EGT-301 For Hunter Syndrome
Jul 31, 2015: biOasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome
Sep 18, 2014: biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria
Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press
Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome
Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase
Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Overview
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Companies Involved in Therapeutics Development
AngioChem Inc
ArmaGen Inc
Bioasis Technologies Inc
Green Cross Corp
Inventiva
JCR Pharmaceuticals Co Ltd
Laboratorios Del Dr Esteve SA
RegenxBio Inc
Sangamo Therapeutics Inc
Shire Plc
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Drug Profiles
AGT-182 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EGT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase beta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JR-032 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JR-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTf-I2S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTfp-I2S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
odiparcil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-913 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Product Development Milestones
Featured News & Press Releases
Oct 26, 2016: National Center for Child Health and Development Initiates Phase 1/2 Trial of Green Cross' idursulfase-beta ICV for the Treatment of Hunter Syndrome with Neurocognitive Decline
Sep 13, 2016: REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV Gene Therapy RGX-121
Jul 05, 2016: REGENXBIO Provides Update On Gene Therapy Development Program RGX-121
Apr 19, 2016: Preclinical Data from REGENXBIO’s RGX-121 Gene Therapy Program to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting
Feb 25, 2016: ESTEVE Provides Update On EGT-301 For Hunter Syndrome
Jul 31, 2015: biOasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome
Sep 18, 2014: biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria
Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press
Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome
Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase
Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by AngioChem Inc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by ArmaGen Inc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Bioasis Technologies Inc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Green Cross Corp, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Inventiva, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Laboratorios Del Dr Esteve SA, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by RegenxBio Inc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Sangamo Therapeutics Inc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Shire Plc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products, H1 2017
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by AngioChem Inc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by ArmaGen Inc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Bioasis Technologies Inc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Green Cross Corp, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Inventiva, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Laboratorios Del Dr Esteve SA, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by RegenxBio Inc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Sangamo Therapeutics Inc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Shire Plc, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects, H1 2017
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products, H1 2017
LIST OF FIGURES
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
AngioChem Inc
ArmaGen Inc
Bioasis Technologies Inc
Green Cross Corp
Inventiva
JCR Pharmaceuticals Co Ltd
Laboratorios Del Dr Esteve SA
RegenxBio Inc
Sangamo Therapeutics Inc
Shire Plc
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
AngioChem Inc
ArmaGen Inc
Bioasis Technologies Inc
Green Cross Corp
Inventiva
JCR Pharmaceuticals Co Ltd
Laboratorios Del Dr Esteve SA
RegenxBio Inc
Sangamo Therapeutics Inc
Shire Plc
